Diagnosis and treatment of 24 cases of primary urethral carcinoma
10.3969/j.issn.1009-8291.2023.12.003
- VernacularTitle:原发性尿道癌24例诊治分析
- Author:
Yangwang JIN
1
;
Meng LIU
1
;
Qiang FU
1
Author Information
1. Department of Urology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Eastern Institute of Urologic Reconstruction, Shanghai 200233, China
- Publication Type:Journal Article
- Keywords:
urethral tumor;
primary urethral carcinoma;
squamous cell carcinoma;
urothelial carcinoma;
survival analysis
- From:
Journal of Modern Urology
2023;28(12):1018-1022
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the clinical characteristics,treatment and prognosis of primary urethral cancer (PUC). 【Methods】 The clinical data of 24 PUC patients treated in our hospital during Jan.2013 and Jul.2022 were retrospectively analyzed. The patients were followed up to monitor the metastasis,recurrence and survival. 【Results】 The patients included 17 male and 7 female,aged (57.6±12.8) years. The main pathologic type was squamous cell carcinoma,followed by urothelial carcinoma. Altogether 23 patients underwent surgical treatment,and 8 of them received postoperative radiotherapy or chemotherapy. During the follow-up of 1 to 92 months,17 patients were followed up,3 of the them had local recurrence,1 had metastasis,and 5 died. Survival analysis showed that patients survived (63.3±10.6) months,with a 21-month survival rate of 64.8% and progression-free survival of 22 (9,72) months. 【Conclusion】 PUC is a rare malignant tumor with poor prognosis. For early and distal PUC,urethra-preserving surgery can be adopted;for proximal or advanced PUC,surgery combined with radiotherapy or chemotherapy is recommended.
